Patient Information Leaflet
Olmesartan/Hydrochlorothiazide Viatris 20 mg/25 mg Film-Coated Tablets EFG
olmesartan medoxomil and hydrochlorothiazide
Read this leaflet carefully before you start taking this medicine because it contains important information for you.
1.What is Olmesartan/Hydrochlorothiazide Viatris and what is it used for
2.What you need to know before you start taking Olmesartan/Hydrochlorothiazide Viatris
3.How to take Olmesartan/Hydrochlorothiazide Viatris
4.Possible side effects
5.Storage of Olmesartan/Hydrochlorothiazide Viatris
6.Contents of the pack and additional information
Olmesartán/Hidroclorotiazida Viatris contains two active ingredients, olmesartán medoxomilo and hidroclorotiazida, which are used in the treatment of high blood pressure (hypertension):
·Olmesartán medoxomilo belongs to a group of medicines called angiotensin II receptor antagonists. It reduces blood pressure by relaxing blood vessels.
·Hidroclorotiazida belongs to a group of medicines called thiazide diuretics. It reduces blood pressure by helping the body to eliminate excess fluids, causing the kidneys to increase urine production.
They will only give youolmesartán medoxomilo/hidroclorotiazidaif treatment with olmesartán medoxomilo alone has not adequately controlled blood pressure. The combined administration of both active ingredients in this medicine contributes to reducing blood pressure more than each substance administered separately.
You may already be taking medicines to treat high blood pressure, but your doctor may want to give youolmesartán medoxomilo/hidroclorotiazidato lower it further.
High blood pressure can be controlled with medicines like olmesartán medoxomilo/hidroclorotiazida tablets. Your doctor may also have recommended that you make some lifestyle changes to help lower your blood pressure (for example, losing weight, quitting smoking, reducing alcohol consumption, and reducing the amount of salt in your diet). Your doctor may also have recommended that you exercise regularly, such as walking or swimming. It is essential to follow your doctor's advice.
If you think any of these cases apply to you or are unsure, do not take the tablets. Talk to your doctor and follow their advice.
Warnings and precautions
Consult your doctorbefore starting to take Olmesartán/Hidroclorotiazida Viatris if you have any of the following health problems:
-Angiotensin-converting enzyme (ACE) inhibitors (for example, enalapril, lisinopril, ramipril), especially if you have kidney problems due to diabetes.
-Aliskiren.
Your doctor may check your kidney function, blood pressure, and the amount of electrolytes (such as potassium) in your blood at regular intervals.
Also see the information in the section "Do not take Olmesartán/Hidroclorotiazida Viatris".
Your doctor may want to see you more often and do some tests if you have any of these conditions.
Olmesartan medoxomil/hydrochlorothiazide may cause an increase in the levels of fats and uric acid in the blood.Your doctor will probably want to do a blood test from time to time to control these possible changes.
A change in the levels in the blood of certain chemical substances called electrolytes may occur. Your doctor will probably want to do a blood test from time to time to control this possible change. Some signs of electrolyte changes are: thirst, dry mouth, muscle pain or cramps, tired muscles, low blood pressure (hypotension), feeling weak, slow, tired, drowsy, or restless, nausea, vomiting, decreased need to urinate, rapid heart rate.Inform your doctor if you notice any of these symptoms.
Like any other medication that reduces blood pressure, an excessive decrease in blood pressure in patients with alterations in blood flow to the heart or brain can cause a heart attack or stroke. Therefore, your doctor will closely monitor your blood pressure.
If you are scheduled to undergo parathyroid function tests, you should stop taking olmesartan medoxomil/hydrochlorothiazide before doing them.
It is reported to athletes that this medication may establish a positive analytical result for doping control.
You should inform your doctor if you think you are (or could be) pregnant.Olmesartan medoxomil/hydrochlorothiazide is not recommended for use at the beginning of pregnancy and should not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if taken at this stage (see Pregnancy section).
During treatment:
Contact your doctor if you experience any of the following adverse effects:
Children and adolescents (under 18 years)
Olmesartan medoxomil/hydrochlorothiazide is not recommended for children and adolescents under 18 years.
Black patients
Like other similar medications, the blood pressure-lowering effect of olmesartan medoxomil/hydrochlorothiazide is somewhat less in black patients.
Other medications and Olmesartán/Hidroclorotiazida Viatris
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication.
In particular, inform your doctor or pharmacist about any of the following medications:
- Potassium supplements (as well as salt substitutes that contain potassium).
- Diuretics.
- Heparin (to thin the blood).
- Laxatives.
- Steroids.
- Adrenocorticotropic hormone (ACTH).
- Amphotericin, an antifungal medication.
- Carbenoxolone (medication for the treatment of mouth and stomach ulcers).
- Penicillin G sodium (antibiotic, also called benzylpenicillin sodium).
- Some analgesics such as aspirin or salicylates.
Your doctor may need to change your dose and/or take other precautions:
If you are taking an ACE inhibitor or aliskiren (see also the information in the sections "Do not take Olmesartán/Hidroclorotiazida Viatris" and "Warnings and precautions").
Taking Olmesartán/Hidroclorotiazida Viatris with alcohol
Be careful when drinking alcohol while taking olmesartan medoxomil/hydrochlorothiazide, as some people may feel weakness or dizziness. If this happens, do not drink any alcohol, including wine, beer, or alcoholic beverages.
Pregnancy and breastfeeding
Pregnancy
You should inform your doctor if you think you are (or could be) pregnant.Your doctor will usually recommend that you stop taking olmesartan medoxomil/hydrochlorothiazide before becoming pregnant or as soon as you know you are pregnant and recommend that you take another medication instead of olmesartan medoxomil/hydrochlorothiazide. Olmesartan medoxomil/hydrochlorothiazide is not recommended for use during pregnancy and should not be administered after the third month of pregnancy, as it may cause serious harm to your baby if administered at this stage.
Breastfeeding
Inform your doctor if you are breastfeeding or about to start it.Olmesartan medoxomil/hydrochlorothiazide is not recommended for use during breastfeeding. Your doctor may choose another treatment if you want to continue breastfeeding.
Consult your doctor or pharmacist before using any medication.
Driving and operating machinery
You may feel drowsy or dizzy while taking treatment for high blood pressure. If this happens, do not drive or operate machinery until the symptoms have disappeared. Consult your doctor.
Olmesartán/Hidroclorotiazida Viatris contains sodium
This medication contains less than 1 mmol of sodium (23 mg) per tablet; it is essentially "sodium-free".
Follow exactly the administration instructions for this medication as indicated by your doctor or pharmacist. If in doubt, consult your doctor or pharmacist again.
The recommended dose is 1 Olmesartán/Hidroclorotiazida Viatris 20 mg/12.5 mg tablet per day. If blood pressure is not adequately controlled, your doctor may change the dose to 1 Olmesartán/Hidroclorotiazida Viatris 20 mg/25 mg tablet per day.
Take the tablet with water. If possible, take your doseat the same time every day, for example, in the morning.
If you take more Olmesartán/Hidroclorotiazida Viatris than you should
If you take more tablets than you should or if a child accidentally ingests one or more tablets, contact your doctor immediately or go to the nearest hospital emergency department and bring the medication packaging with you. Signs of an overdose may include feeling unwell or drowsy, low blood pressure causing weakness or dizziness, changes in the speed or rhythm of the heartbeat, or excessive thirst.
In case of an overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone: 91 562 04 20, indicating the medication and the amount ingested.
If you forget to take Olmesartán/Hidroclorotiazida Viatris
If you forget to take a dose, take your usual dose the next day as usual.Do nottake a double dose to make up for the missed doses.
If you interrupt treatment with Olmesartán/Hidroclorotiazida Viatris
It is essential to continue taking olmesartan medoxomil/hydrochlorothiazide, unless your doctor tells you to stop treatment.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medications, this medication may cause side effects, although not everyone will experience them.
If you experience any of the following side effects, stop takingolmesartán medoxomilo/hidroclorotiazidaand contact your doctor or go to the nearest hospital emergency department immediately:
Rare(may affect up to 1 in 100 people):
Rare(may affect up to 1 in 1,000 people):
Very rare(may affect up to 1 in 10,000 people):
Unknown frequency(cannot be estimated from available data):
Olmesartán medoxomilo/hidroclorotiazida may cause a significant drop in blood pressure in susceptible patients or as a result of an allergic reaction.Less frequently, dizziness or weakness may occur.If this happens, stop taking olmesartánmedoxomilo/hidroclorotiazida, consult your doctor immediately, and remain lying down in a horizontal position.
Olmesartán medoxomilo/hidroclorotiazida is a combination of two active principles, and the following information first describes the side effects reported so far with the combination of olmesartán medoxomilo and hidroclorotiazide (in addition to those mentioned above) and, secondly, the side effects known of the two active principles separately.
These are other side effects known so far with olmesartán medoxomilo and hidroclorotiazide taken simultaneously:
If these effects occur, they are often mild anddo not need to interrupt treatment.
Frequent(may affect up to 1 in 10 people):
Rare(may affect up to 1 in 100 people):
Also, less frequently, some changes in blood test results have been observed, including:
Increased levels of blood fat, increased urea or uric acid in the blood, increased creatinine, increased or decreased potassium levels in the blood, increased calcium levels in the blood, increased blood sugar, increased values in liver function tests. Your doctor will monitor this through a blood test and tell you if you need to take any action.
Rare(may affect up to 1 in 1,000 people):
Very Rare(may affect up to 1 in 10,000 people):
Also, in rare cases, some changes in blood test results have been observed, including:
Increased urea nitrogen in the blood, decreased hemoglobin and hematocrit values. Your doctor will monitor this through a blood test and tell you if you need to take any action.
Additional side effects reported with the use of olmesartán medoxomilo or hidroclorotiazide alone, but not with olmesartánmedoxomilo/hidroclorotiazide:
Olmesartán medoxomilo:
Frequent(may affect up to 1 in 10 people):
Also, frequent changes in blood test results have been observed, including:
Increased levels of substances that measure muscle function.
Rare(may affect up to 1 in 100 people):
Rare(may affect up to 1 in 1,000 people):
Very rare(may affect up to 1 in 10,000 people):
Hidroclorotiazida:
Frequent(may affect up to 1 in 10 people):
Also, some changes in blood test results have been observed, including:
Decreased levels of chloride, magnesium, or sodium in the blood, increased serum amylase (hyperamylasemia).
Rare(may affect up to 1 in 100 people):
Rare(may affect up to 1 in 1,000 people):
Very rare(may affect up to 1 in 10,000 people):
Unknown frequency(cannot be estimated from available data):
Reporting of side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for the Pharmacovigilance of Medicines for Human Use: https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not store at a temperature above 25°C.
Do not use this medication after the expiration date that appears on the packaging and on the blister, after CAD. The expiration date is the last day of the month indicated.
Medications should not be disposed of through drains or in the trash. Dispose of the containers and medications you no longer need at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of the containers and medications you no longer need. By doing so, you will help protect the environment.
Olmesartan/Hydrochlorothiazide Viatris Composition
Each tablet contains 20 mg of olmesartan medoxomil and 25 mg of hydrochlorothiazide.
The other components are:
(tablet core) sodium croscarmellose (E466), mannitol (E421), microcrystalline cellulose (E460i), low-substituted hydroxypropylcellulose (E463), anhydrous colloidal silica (E551), magnesium stearate (E572), sodium lauryl sulfate (E487) and
(tablet coating) hypromellose (E464), titanium dioxide (E171), macrogol, talc (E553b), yellow iron oxide (E172), red iron oxide (E172). See section 2 “Olmesartan/Hydrochlorothiazide Viatris contains sodium”.
Appearance of the product and contents of the package
Olmesartan/Hydrochlorothiazide Viatris are yellow-coated, oblong, biconvex, beveled-edge tablets, marked with “M” on one face and “H5” on the other.
It is available in blister packs of 14, 28, 30, 56, 90, and 98 tablets and calendar packs of 28 tablets.
Only some package sizes may be marketed.
Marketing Authorization Holder
Viatris Limited
Damastown Industrial Park
Mulhuddart, Dublin 15
Dublin
Ireland
Responsible for Manufacturing
McDermott Laboratories t/a Gerard Laboratories, 35/36 Baldoyle Industrial Estate, Grange Road, Dublin 13, Ireland
Mylan Hungary Kft.
H-2900, Komárom
Mylan utca 1
Hungary
For more information about this medicine, please contact the local representative of the marketing authorization holder:
Viatris Pharmaceuticals, S.L.
C/ General Aranaz, 86
28027 - Madrid
Spain
This medicine is authorized in the member states of the European Economic Area with the following names:
Spain | Olmesartan/Hydrochlorothiazide Viatris 20 mg/12.5 mg, 20 mg/25 mg film-coated tablets |
Greece | Olmesartan/HCTZ Mylan 20 mg/12.5 mg, 20 mg/25 mg film-coated tablets |
Ireland | Olmesartan medoxomil/Hydrochlorothiazide 20 mg/12.5 mg, 20 mg/25 mg film-coated tablets |
Portugal | Olmesartan + Hidroclorotiazida Mylan |
Last reviewed date of this leaflet: April 2023
More detailed information about this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)(https://www.aemps.gob.es/)
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.